To clarify the role of fragile histidine triad (FHIT) in hematological malignancies, we examined the methylation status and the expression level of the FHIT gene in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) cells in comparison with the methylation of the p15 INK4B gene. The FHIT methylation was found in 13 of 94 (13.8%) AML and 22 of 40 (55.0%) MDS cases, but not in normal mononuclear cells (MNCs). Both the frequency and density of methylation increased in the advanced-stages MDS and the relapsed AML cases. Although FHIT and p15 INK4B methylations were not correlated in MDS and AML, increased FHIT methylation at the relapse in AML was associated with p15 INK4B methylation. The median expression level in AML was significantly higher than in normal MNCs, although the median expression level in those with methylation was significantly lower than in those without methylation. Furthermore, the methylation level at relapse was significantly higher than at diagnosis in AML. These results suggested that FHIT methylation was accumulated through the disease progression of MDS and AML, and the role of the FHIT gene as a tumor suppressor seemed different in AML and MDS.
Introduction
The fragile histidine triad (FHIT) gene was isolated from the chromosome band 3p14.2, which includes the FRA3B common fragile region. 1 Alterations of the FHIT gene, including loss of heterozygosity, homozygous deletions and the expression of aberrant transcripts, are frequently found in a variety of solid tumors and cancer cell lines, and the loss or reduced expression of FHIT is reportedly associated with tumor progression and worse prognosis. [2] [3] [4] [5] The FHIT gene has, therefore, been considered a tumor suppressor gene, while the exact molecular pathway of its tumor suppressor function remains unclear. 6 In hematological malignancies, aberrant FHIT transcripts have been reported in acute and chronic leukemia, although it was demonstrated that those aberrant transcripts were observed in both normal and malignant hematopoietic cells. [7] [8] [9] [10] In contrast, the loss or reduced expression of FHIT protein was restricted to malignant hematopoietic cells, while neither loss nor reduction was associated with progression, response to therapy or prognosis in chronic myeloid leukemia (CML) and prognosis in acute lymphocytic leukemia (ALL). 11, 12 These results indicated that inactivating alterations of the FHIT gene, which result in the loss or reduced expression of its product, may be involved in the pathogenesis of hematological malignancies, but the clinical significance was not well documented. Since genomic alterations of the FHIT gene, such as loss of heterozygosity and somatic mutations, are rare in hematological malignancies, we focused on promoter methylation as an inactivating mechanism. To date, it has been shown that many tumor suppressor genes were inactivated by methylation within their promoter regions in various kinds of malignant cells. Among them, it was demonstrated that the p15 INK4B gene, but not the p14 ARF and p16
INK4A
genes, was frequently inactivated by promoter methylation in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). 13 In particular, p15 INK4B was shown to be associated with the high blast percentage in BM and transformation to AML in MDS. [14] [15] [16] Methylation of the FHIT gene was found in several solid tumors, including the esophagus, colon, lung and breast cancers, and was shown to be associated with loss of expression. [17] [18] [19] In addition, it was reported that the loss or reduced expression of FHIT protein resulting from gene methylation was associated with disease progression in solid tumors. [20] [21] [22] However, it was also suggested that FHIT inactivation seems to occur at different stages of cancer development among the cancer types and is necessary, but not sufficient, for conferring a growth advantage to cancer cells. 23 In this study, to clarify how FHIT is involved in the development and progression of hematological malignancies, we examined the methylation status and expression level of the FHIT gene in MDS and AML cells in comparison with p15 INK4B methylation.
Methods

Patients and samples
The diagnosis of MDS and AML was based on morphology, histopathology, the expression of leukocyte differentiation antigens and/or the French-American-British (FAB) classification. The study population included 40 MDS cases consisting of 10 refractory anemia (RA), 13 refractory anemia with excess of blasts (RAEB), five RAEB in transformation (RAEBt), seven overt leukemia from MDS (MDS-overt) and five chronic myelomonocytic leukemia (CMMoL) and 94 newly diagnosed de novo AML cases consisting of 1 M0, 26 M1, 31 M2, 6 M3, 20 M4, 9 M5 and 1 M6 FAB types. In 21 of the 94 AML cases, samples at both diagnosis and at the first relapse were available. In three of the 21 cases, sequential samples at diagnosis, complete remission (CR) and the first relapse were available. Furthermore, in six cases, samples at both diagnosis and CR were available. Bone marrow (BM) samples from patients with MDS or AML were subjected to Ficoll-Hypaque (Pharmacia LKB, Uppsala, Sweden) density gradient centrifugation and cryopreserved in liquid nitrogen before use. For the normal control, five BM, four peripheral blood (PB) and five cord blood (CB) mononuclear cells (MNCs) were used. We obtained informed consent from all patients and volunteers to use their samples in this study. CB was collected after full-term deliveries with informed consent approved by the Review Board of Tokai Cord Blood Bank. 24 
CD34
þ and CD34 À fractions of MDS, CB and BM MNCs were separated by using Dynabeads M-450 conjugated with an anti-CD34 monoclonal antibody and DETACHaBEAD (Dynal, Oslo, Norway), according to the manufacturer's instructions. Separated samples were subjected to flow cytometry for analyzing the purity. We also examined three human myeloid leukemia cell lines consisting of THP1, MOLM13 and U937. All cell lines were maintained in RPMI1640 medium (Gibco BRL, Gaithersburg, ND, USA) supplemented with 10% fetal calf serum (Gibco BRL).
Analysis of FHIT and p15
INK4B gene methylation
In this study, we analyzed the methylation status of 30 CpG sites in the FHIT gene promoter and tentatively numbered them from 5 0 to 3 0 (Figure 1 ). High molecular weight DNA was prepared from cell samples and cell lines by standard methods, and bisulfite modification of genomic DNA was performed as previously reported. 25 Methylation-specific PCR (MSP) was performed by using primer pairs for the methylated FHIT gene 
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Amplified products were separated through agarose gel and purified using a QIAquick gel extraction kit (Qiagen Inc., Chatsworth, CA, USA). The fragments were cloned into a pGEM-T-vector (Promega, Madison, WI, USA), then transfected into the Escherichia coli strain, DH5a. In total, 10 recombinant colonies were randomly selected from PCR-amplified libraries, and plasmid DNA was prepared using a QIAprep Spin Miniprep Kit (Qiagen Inc. (Figure 1b) .
Quantitation of FHIT transcript expression
Total RNA was extracted from the samples using a QIAamp RNA Blood Mini Kit (Qiagen Inc.). cDNA was synthesized from each RNA using a random primer and Moloney murine leukemia virus reverse transcriptase (Super-Script II; Gibco BRL, Gaithersburg, ND, USA), according to the manufacturer's recommendations. The expression level of the FHIT transcript was quantitated using a real-time fluorescence detection method on an ABI Prism 7000 sequence detection system (Applied Biosystems). 27 The primer and probe sequences for real-time PCR of FHIT were sense primer, 5
0 -AAACATTTCCA TGGGACCTCTCT-3 0 , antisense primer, 5 0 -GAGCTCCTCATAG ATGCTGTCATTC-3 0 , and TaqMan probe, 5 0 -FAM-CCGGACA GACTGTGAAGCACGTTCAC-TAMRA-3 0 . The housekeeping gene, GAPDH, served as a control for cDNA quality. Relative gene expression levels were calculated using standard curves 
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5-Aza-2 0 -deoxycytidine treatment 5-Aza-2 0 -deoxycytidine (5-Aza-dC) was purchased from Sigma Chemical Co. (St Louis, MO, USA), and dissolved in phosphatebuffered saline at appropriate concentrations. Primary AML and MDS cells or cell lines were plated at a density of 1 Â 10 6 cells/ ml on a six-well tissue plate (Becton Dickinson, Franklin Lakes, NJ, USA) in RPMI1640 medium (Gibco BRL) containing 10% FCS with or without 1 mM 5-Aza-dC. In this culture condition, we did not add any growth factors. After 48 h treatment in a humidified incubator containing 5% CO 2 in air at 371C, DNA and RNA were extracted from the treated cells and subjected to analysis for methylation status and expression of the FHIT gene as described above.
Statistical analysis
Differences in continuous variables were analyzed with the Mann-Whitney U-test for distribution between two groups, or the Kruskal-Wallis test and the Bonferroni test for distribution among more than three groups. Analysis of frequency was performed using Fisher's exact test for 2 Â 2 tables or Pearson's w 2 test for larger tables. Analyses of the change of methylation density and the expression level of the transcript were performed using the paired sign test and the Wilcoxon signed rank test, respectively. These statistical analyses were performed with StatView-J 5.0 (Abacus Concepts Inc., Berkeley, CA, USA). For all analyses, the P-values were two-tailed, and a P-value of less than 0.05 was considered statistically significant.
Results
Methylation status of the FHIT gene promoter
Since the MSP used here detected the methylation status only in the 3 0 region of the promoter, we first examined whether MSP represented the methylation density of 30 CpG sites in the FHIT gene promoter of three leukemia cell lines and 14 normal MNCs. To determine the methylation density, we performed BGS in 10 randomly selected clones from the PCR-amplified libraries of each sample and the methylation density was determined by the number of methylated CpG/total number of CpG sites. In all normal MNCs, no visible products amplified with methylation-specific primers were observed, in agreement with the results obtained by BGS where there was only one methylated CpG site among all the analyzed clones. Furthermore, no methylated CpG site was observed by BGS in both CD34 þ and CD34 À fractions separated from each two CB and BM cells. In THP1, MSP revealed unmethylated and weak methylated forms, and the BGS demonstrated that 9/10 clones had at least one methylated site and the methylation density was 13.3%. In U937, MSP revealed both unmethylated and methylated forms, and BGS demonstrated that 8/10 clones had methylated sites and the methylation density was 29.7%. In MOLM13, MSP revealed faint unmethylated and strong methylated forms, and the BGS demonstrated that all clones had methylated sites and the methylation density was 91.0% (Figure 2a ). Since the BGS demonstrated that all clones had methylated sites in MOLM13, the DNA of MOLM13 was serially diluted with that of normal PB MNCs to determine the sensitivity of MSP. As shown in Figure 2b , MSP could detect the methylated DNA at the 10 À2 level. These results indicated that MSP was sensitive and the methylation status obtained by MSP essentially reflected the methylation density of 30 CpG sites. We therefore used MSP to examine the methylation status of the clinical samples. In addition, we classified the methylation status into four levels according to MSP: no methylation, only the unmethylated form was detected; weak methylation, the unmethylated form was stronger than the methylated form; moderate methylation, unmethylated and methylated forms were visible at the same level; strong methylation, the methylated form was stronger than the unmethylated form. In de novo AML, there was no different distribution of the methylation status among the FAB types. Furthermore, it was notable that eight of 13 methylated AML cases revealed weak methylation, and two and three cases revealed moderate and strong methylation, respectively (Table 1) . Since the BM cells of these AML cases with FHIT methylation contained over 80% blast cells, the weak methylation status did not result from the lower percentage of blast cells in BM.
In MDS, the FHIT methylation frequency was significantly higher in cases with advanced-stage RAEB (8/13, 61.5%), RAEBt (4/5, 80%) or MDS-overt (6/7, 85.7%) than in those with earlystage RA (1/10, 10%). It was particularly interesting that the methylation level became moderate or strong in advanced-stage MDS in contrast to de novo AML (Table 1 ). In addition, three of five cases with CMMoL showed FHIT methylation, all of which had strong levels ( Table 1) . Since the BM cells from MDS contains heterogeneous cell populations, we analyzed the methylation status of CD34 þ and CD34 À fractions separated from 10 MDS samples and compared them with the results obtained by using a total MNCs. Each of the separated CD34 þ and CD34 À fractions contained over 85% and less than 10% CD34 þ cells, respectively. In four MDS samples, the methylation levels of CD34 þ fractions were the same as those of CD34 À fractions. In three samples, the methylation levels of CD34 þ fractions were stronger than those of CD34 À fractions, while those of CD34 þ fractions were weaker than CD34
À fractions in three samples (Figure 3 ). (Table 2) . However, p15
INK4B methylation was frequently observed in advancedstage MDS in agreement with the previous reports ( Table 1 ).
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Quantitation of the expression level of the FHIT transcript
To analyze the effect of FHIT methylation on its transcript expression, we quantitated the expression level of the FHIT transcript in AML and MDS cells as well as normal MNCs using a real-time fluorescence detection method. We evaluated the cDNA quality from each GAPDH expression, then the ratio of the FHIT Ct value to GAPDH Ct value (FHIT/GAPDH) was determined as the FHIT expression level. In normal MNCs, the median expression level of the FHIT transcript was 0.134 (range, 0.028-1.654). The median expression levels in de novo AML and MDS were 1.445 (range, 0-81.7) and 0.6 (range, 0.040-15.3), respectively, and the Bonferroni test revealed that distributions were significantly higher in de novo AML than those in normal MNCs (Po0.0001) (Figure 4a ).
According to the methylation status, the median expression level in de novo AML without methylation (1.669; range, 0-81.7) was significantly higher than those with methylation (0.474; range, 0-1.320) (P ¼ 0.0008) and in normal MNCs (Po0.0001). In contrast, the median expression level in MDS was not related to the methylation status (0.637, range, 0.086-15.3 in MDS without methylation; 0.444, range, 0.040-2.775 in MDS with methylation) (Figure 4b ). 
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Sequential analysis of FHIT methylation in AML
In 21 AML cases, the methylation status was analyzed at both initial diagnosis and the first relapse (Table 3) . FHIT methylation was observed in four cases at initial diagnosis, but not in the remaining 17 cases. Among four cases harboring FHIT methylation at initial diagnosis, three cases also showed methylation at the first relapse, although one case lost the methylation. Furthermore, increase of the methylation level from weak to strong was observed in one case during the first relapse. Among 17 cases without FHIT methylation at initial diagnosis, the FHIT gene was still not methylated at the first 
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relapse in nine cases, although eight cases revealed methylation at the first relapse. The paired sign test revealed that the methylation level at the first relapse was significantly higher than that at diagnosis (P ¼ 0.0215). However, the expression level of the FHIT transcript at the first relapse was not affected by the increased methylation status (P ¼ 0.1823 by the Wilcoxon signed rank test). Although FHIT methylation was not associated with p15 INK4B methylation at diagnosis, it was particularly interesting that all nine cases, which had increased FHIT methylation level at the first relapse, revealed p15 INK4B methylation at the first relapse.
In addition, we sequentially analyzed the methylation and expression level of the FHIT gene at diagnosis, CR and the first relapse in three AML cases. Although we found no methylation at any point in two cases, one case had a dramatic change of methylation status and the expression level of the FHIT gene. In this case, FHIT methylation was found both at diagnosis and the first relapse, but not at CR. In agreement with the methylation status, the FHIT expression level was five times higher at CR than at diagnosis and first relapse. These results provided clinical correlation that the FHIT expression was downregulated by its promoter methylation (data not shown).
In six cases, both samples at diagnosis and CR were available. Furthermore, CD34
þ and CD34 À fractions separated from the BM samples at CR were analyzed. At diagnosis, FHIT methylation was found in three cases, but not in both CD34 þ and CD34 À fractions from all cases at CR by MSP. These results were confirmed by BGS ( Figure 5 ). Taken together, we found no FHIT methylation in nine BM samples at CR, suggesting that the conventional chemotherapeutic agents for AML did not induce FHIT methylation.
Effect of 5-Aza-dC treatment on FHIT methylation and expression
Previously, it was demonstrated that 1 mM 5-Aza-dC treatment for 6 days demethylated the FHIT gene in lung cancer cell lines, resulting in re-expression of the FHIT transcript. 18 However, since our preliminary experiment revealed that most primary AML cells resulted in apoptosis after 5-Aza-dC treatment for 6 days, we evaluated the FHIT methylation status and expression level in eight primary samples and three human myeloid leukemia cell lines (THP1, MOLM13 and U937) 2 days after 1 mM 5-Aza-dC treatment ( Figure 6 ). In THP1 and MOLM13, 5-Aza-dC treatment decreased each FHIT methylation level and increased each expression level of the FHIT transcript. In U937, the methylation level was not changed by 5-Aza-dC treatment, while the expression level was increased. In four of the eight primary samples, each methylation level was decreased and 
Discussion
The initiation and development of cancer involves several molecular changes, including epigenetic alterations as well as genetic alterations. 28, 29 The methylation of the promoter region of the gene is an important mechanism of epigenetic regulation resulting in gene inactivation. In this study, we demonstrated that FHIT methylation is significantly associated with AML and MDS, and that both the frequency and density of FHIT methylation increased with the disease progression of MDS. In contrast, FHIT methylation was not observed in normal CB, BM and CR samples. À fractions might be derived from non-MDS clones such as lymphocytes. Further analysis using the precisely fractionated samples according to the cell lineage will be required. It remains unclear why in samples of UPN 122, 127 and 141, FHIT methylation was dominant in CD34 À fractions. It should be considered that the unmethylated cell population is not necessarily derived from a normal clone. In CD34 þ fraction of UPN141, p15 INK4B was partially methylated in contrast to FHIT. Methylation status may be changed during differentiation of MDS cells. In the future, clonogenic assay distinguishing between normal and MDS clones will clarify the significance of the methylation status of the progenitor cells.
The FHIT methylation was not found so frequently and its density was weak in de novo AML at diagnosis, while both the frequency and density significantly increased at the first relapse. These results indicated that the FHIT methylation was accumulated through the disease progression of AML as well as MDS. However, FHIT seemed to be differently involved in the disease progression between MDS and AML. Both FHIT and p15
INK4B
methylation increased according to the advanced stages of MDS, although these were not correlated with each other, suggesting the independent involvement of FHIT and p15 INK4B . In AML, these methylations were not correlated at diagnosis, while the FHIT methylation level significantly increased at the first relapse in cases where p15 INK4B methylation was observed at the first relapse, suggesting that the tumor suppressor function of FHIT may be effective in collaboration with p15 INK4B . Alternatively, increased methyltransferase activity during disease progression may induce FHIT methylation.
It was reported that FHIT methylation was closely associated with the loss or reduction of FHIT expression in several kinds of solid tumors, and that the loss of FHIT expression was also observed in hematological malignancies. However, when the median expression level of the FHIT transcript in the methylated and unmethylated cases was compared with de novo AML, the former level was indeed lower than the latter, but was the same as that in normal MNCs. At present, it is not clear why the expression level of the FHIT transcript is higher in de novo AML and MDS cells than that in normal MNCs. It is possible that FHIT expression is not involved in the pathogenesis of AML and/or MDS at the early stage. On the other hand, previous reports demonstrated that aberrant FHIT transcripts were frequently found rather than a loss of expression in hematological malignancies, while our quantitative conditions detected a total of expressed FHIT transcript regardless of aberrant transcripts. 30, 31 Therefore, it is necessary to determine which transcripts are dominantly expressed in AML and MDS cells. In addition, since the reduced expression level of FHIT protein is reportedly restricted to malignant hematopoietic cells, the relationship of expression levels between the transcript and protein should be clarified. It was shown that replacement or overexpression of the wild-type FHIT gene in human cancer cell lines reduced tumorigenicity and growth rate. 32, 33 In contrast, introduction of the wild-type FHIT gene did not alter the tumorigenicity in HeLa cells. 34 Furthermore, it was reported that only half the renal-cell-carcinoma cell lines were suppressed by exogenous FHIT expression. 35 Therefore, there seems to be À fractions from all CR samples. Each methylation density obtained by BGS is also indicated. U and M indicate unmethylated and methylated PCR products, respectively. some different effects of FHIT expression on the pathogenesis among cancer cell types. In this study, the expression level of the FHIT transcript was not related to any clinical variables (data not shown). However, since the expression level decreased in association with methylation at the first relapse of de novo AML and at advanced stages of MDS, and the expression level increased by treatment with 5-Aza-dC, the reduced expression of the FHIT transcript caused by methylation might be involved in the pathogenesis of disease progression in AML and MDS.
In conclusion, frequent methylation of the FHIT gene was associated with disease progression, and the role of the FHIT gene as a tumor suppressor seemed to be important at a later phase during the development of AML and MDS. In addition, a tumor suppressor function of FHIT may be more effective on the pathophysiology of MDS and AML when additional genes alterations would be accumulated. Further analysis is required to clarify the cooperative function of FHIT with other tumor suppressor genes as well as oncogenes.
